Home Page - ChinaBio® Today

The finalists will present to a judges panel made up of venture capitalists, scientists, industry executives and others. There will also be industry experts speaking on the industry and entrepreneurships. The event will end with the prize ceremony followed by a reception. Attendees will include the finalists, other entrants, government representatives, industry executives, venture capitalists and investors, delegates from the press and interested parties from life science companies and universities.

>> See www.SEED2010.com for more information on the SEED events

ChinaBio® Today - Focused solely on China biotech...

China is already the fastest growing market in the world for pharmaceuticals. Now, after billions of dollars of investment, China is transforming itself into a world leader in biotechnology. ChinaBio® Today focuses exclusively on the rapidly evolving biotech industry in China. From our offices in Shanghai and California, we provide daily news, commentary and analysis on public and private China biotechnology companies and industry events, as well as global issues affecting the China life science market.

Email subscriptions are free. Just click here to register for free daily summaries of key events in China biotech. Paid subscriptions provide full access to all articles and analysis, including the over 2000 articles we've published on the biotech industry over the last four years. There is also an option to contact our analysts to answer your questions. Click here to learn more about our subscription plans.

Recent Articles

First event iApply to present now! Deadline: April 30

Recent Articles

FDA Issues Warning to China API Maker (in: News & Analysis) Mar 15, 2010: The FDA has told XiAn Libang Pharmaceuticals to improve its quality control procedures, if it wants to continue importing products to the US. The US agency told the company to hire an outside auditor to develop a Corrective Action Plan and respond to the warning letter within 15 days. According to the FDA, XiAn Libang did not conduct a thorough investigation after quality control problems were discovered last summer. More details...

The Week in Review: AutekBio Raises $100 Million for Biologic CMO (in: Week in Review) Mar 13, 2010: AutekBio raised $100 million to build Asia’s largest biologic CMO facility in Beijing; Porton Fine Chemicals announced a $10 million funding to expand its CMO capacity; TCT Medical Technology, an OB/GYN company, booked $10 million in new capital from two Fidelity funds; EA Inc., which makes invisible dental braces, raised $6.6 million Series A from OrbiMed; Lotus Pharma (路坦制药有限公司) began building a combined office, R&D, production, and storage facility; Dr. Xiaochuan Wang, who founded Sundia MediTech (桑迪亚医药技术（上海）有限公司), was named the Asia-Pacific Entrepreneur of the Year by BioSpectrum; and WuXi PharmaTech (药明康德) reported 2009 net revenues of $270 million, an increase of 7%, and net income of $53 million. More details…

Stock Symbols: (OTCBB: LTUS) (NYSE: WX)

Chongqing Porton Secures $10 Million for Production Facility (in: Deals & Financings) Mar 12, 2010: Chongqing Porton Fine Chemicals Co., a CMO, raised $10 million from the Chongqing DT Fund. The Chongqing DT Fund is a joint effort run by DT Capital of Shanghai and funded by the Chongqing Venture Capital Guidance Fund. Porton will use the money to build a state-of-the-art intermediate and API manufacturing facility in Changshou Chemical Park in Chongqing. More details...

TCT Medical Books $10 Million Investment from Fidelity (in: Deals & Financings) Mar 11, 2010: TCT Medical Technology, a China medical device company that focuses on the OB/GYN market, has raised $10 million in new capital from two Fidelity funds. TCT claims to be the largest high-tech medical equipment and supplies importer in China within women’s health. It is the exclusive distributor in China of Cytyc’s ThinPrep pap test, the world’s leading cervical cancer screening product. More details...

Sundia MediTech Founder Receives “Entrepreneur of the Year” Award (in: News & Analysis) Mar 11, 2010: Xiaochuan Wang, PhD, a returnee who founded Shanghai’s CRO Sundia MediTech (桑迪亚医药技术（上海）有限公司) in 2004, was named the Asia-Pacific Entrepreneur of the Year by BioSpectrum. From its beginnings in 2004, Sundia has grown to an organization with 400 employees, including more than 300 scientists, which offers CRO services to over 90 customers from the US, Europe and Japan. More details...

EA Inc. Raises $6.6 Million from OrbiMed (in: Deals & Financings) Mar 10, 2010: EA Inc., a company that makes invisible dental braces, completed a $6.6 million Series A financing led by OrbiMed, which provided “nearly all” of the funds, along with individual investors. OrbiMed characterized the financing as a restructuring of EA Inc. More details...

Lotus Pharma Breaks Ground on New Building (in: News & Analysis) Mar 10, 2010: Lotus Pharmaceuticals (路坦制药有限公司) has begun construction of nine-storey building complex that will provide offices, R&D, production, and storage. The new facility is being built on the grounds of its existing production facility in Beijing. More details...

Stock Symbol: (OTCBB: LTUS)

AutekBio to Build Largest Biologic CMO in Asia (in: Deals & Financings) Mar 9, 2010: AutekBio, Inc., with headquarters in the Bay Area of California but operations in China, will build Asia’s largest biologic CMO facility in southern Beijing. To construct the facility, AutekBio signed a deal securing $100 million in venture capital from private and government sources. Contributing to the capital raise were SUMA Ventures and Beijing E-Town Harvest International Capital Management Corporation, Beijing’s Municipal Government’s venture capital group. More details...

WuXi PharmaTech Reports Solid Performance in 2009 (in: News & Analysis) Mar 8, 2010: As expected, WuXi PharmaTech (药明康德) reported 2009 net revenues of $270 million, an increase of 7%. Net income climbed to $52.9 million compared to a loss of $64.2 million in 2008, when the company took a significant $49.3 million writedown of its US-based biologics manufacturing business, which was part of its AppTec acquisition. Revenues matched analysts’ expectations, while earnings were slightly below forecasts. More details...

Stock Symbol: (NYSE: WX)

The Week in Review: China Life Science to Grow 22% Per Year Through 2013 (in: Week in Review) Mar 6, 2010: IMS Health predicts China’s drug market will see a 22% CAGR during 2010-2113, compared to 4%-6% worldwide; fifteen early stage China life science entrepreneurs were selected as Finalists in the SEED Competition; Chi-Med may IPO its drug development arm, Hutchison MediPharma, possibly on Nasdaq; WuXi PharmaTech (药明康德) struck a two-way pre-clinical services deal with a J&J subsidiary; aTyr Pharma received a second 18-month grant to fund research at its Hong Kong subsidiary; Sanofi-Aventis is seeking additional partnerships in China; Asymchem Labs will build another manufacturing plant in TEDA; Mindray Medical (迈瑞医疗国际有限公司), released very positive financial results and raised $150 million in new cash; Biostar Pharma expects a 35% increase in 2010 revenues; and Kalen Biomedical found a China distribution partner for its research products. More details…

Stock Symbols: (NYSE: RX) (AIM: HCM) (NYSE: WX) (NYSE: JNJ) (NYSE: SNY) (NYSE: MR) (OTCBB: BSPM)